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Objective: To compare educational, occupational, legal, emotional, substance use disorder, and 
sexual-behavior outcomes in young adults with persistent and desistent attention-
deficit/hyperactivity disorder (ADHD) symptoms and a local normative comparison group (LNCG) 
in the Multimodal Treatment Study of Children with ADHD (MTA).  
Method: Data were collected 12, 14, and 16 years post-baseline (mean age 24.7 years at 16 years 
post-baseline) from 476 participants with ADHD diagnosed at age 7-9, and 241 age- and sex-
matched classmates. Probands were subgrouped on persistence vs. desistence of DSM-5 symptom 
count. Orthogonal comparisons contrasted ADHD vs. LNCG and Symptom-Persistent (50%) vs. 
Symptom-Desistent (50%) subgroups. Functional outcomes were measured with standardized and 
demographic instruments. 
Results: Three patterns of functional outcomes emerged. Post-secondary education, times fired/quit 
a job, current income, receiving public assistance, and risky sexual behavior showed the most 
common pattern: the LNCG fared best, Symptom-Persistent ADHD worst, and Symptom-Desistent 
ADHD between, with largest effect sizes between LNCG and Symptom-Persistent ADHD. In the 
second pattern, seen with emotional outcomes (emotional lability, neuroticism, anxiety disorder, 
mood disorder) and substance use outcomes, the LNCG and Symptom-Desistent ADHD did not 
differ, but both fared better than Symptom-Persistent ADHD. In the third pattern, noted with jail 
time (rare), alcohol use disorder (common), and number of jobs held, group differences were not 
significant. The ADHD group had 10 deaths compared to one in the LNCG. 
Conclusion: Adult functioning after childhood ADHD varies by domain and is generally worse 
when ADHD symptoms persist. It is important to identify factors and interventions that promote 
better functional outcomes.  















Controlled prospective follow-up studies of children with attention-deficit/hyperactivity 
disorder (ADHD) generally document significantly worse adult educational, occupational, social, 
and emotional impairment than in matched non-ADHD controls.1–5 Previous prospective follow-up 
studies of children with ADHD have also indicated that adult outcome is not uniform, with many 
having continuing symptoms and impairment, some being severely functionally impaired while 
others (about 30%) functioning comparably to matched controls.1–7 What characterizes these 
different subgroups is not always clear. 
Recent reports3,7 have suggested functional outcome differences between participants with 
persisting vs. desisting ADHD symptoms. However, persistence of ADHD symptoms in these 
studies is not always optimally defined8 and small sample sizes  make subgrouping on symptom 
persistence difficult. 
The seven-site MTA study followed 579 children aged 7-9 with systematically diagnosed 
(using DSM-IV criteria via parent DISC and teacher reports) ADHD (combined-type) and 258 age- 
and sex-matched classmates without ADHD comprising a Local Normative Comparison Group 
(LNCG).  Assessments were performed at 2, 3, 6, 8, 10, 12, 14, and 16 years post-baseline. This 
provides a highly diverse,9 representative, generalizable sample,10 and the largest to date. 
DSM-5 symptom-count criteria for adults from multiple informants on the Conners’ Adult 
ADHD Rating Scale (CAARS)11 were used to define persistence of symptoms. The diagnostic 
properties of the CAARS vs. DISC were compared and the CAARS was superior in its diagnostic 
specificity and sensitivity.8 Evaluating functional outcomes in many domains (educational, 
occupational, legal, emotional, substance use, and sexual behavior) can provide a comprehensive 
view of the long-term impairments of ADHD vs. LNCG groups and between ADHD subgroups with 














We formulated two hypotheses based on previous MTA follow-ups12 and the accumulated 
literature:1–4 (a) adults with childhood-diagnosed ADHD will be significantly worse than the LNCG 
on multiple functional outcomes; (b) ADHD cases with continuation of symptoms (symptom 
persistence) will have worse outcomes in multiple functional domains than those with symptom 
remission (symptom desistence). 
METHOD 
Sample 
The MTA was originally designed to evaluate effects of treatments in a 14-month 
randomized clinical trial of 579 children (7-9.9 years old) assigned to 4 conditions: systematic 
medication management, multicomponent behavioral treatment, their combination, and treatment as 
usual in community care. After this treatment-by-protocol phase, the MTA continued as a 
naturalistic follow-up study. At the first follow-up (2 years post-baseline), the LNCG – 289 
classmates (258 without ADHD) matched on age and sex– was added when the ADHD participants 
were 9-12 years old. Follow-up assessments continued during childhood (3 years post-baseline), 
throughout adolescence (6, 8, and 10 years post-baseline), and into adulthood (12, 14, and 16 years 
post-baseline). Age range in adulthood was 19-28 years (mean=24.7). Written informed consent was 
obtained with procedures approved by local IRBs. Overall retention in adulthood (assessed at least 
once in the three adult assessments) was 476/579 (82%) for the ADHD group and 241/258 (93%) 
for the non-ADHD LNCG. Similar to adolescent attrition,12 participants lost at 16-year follow-up 
had, at baseline, significantly lower family income, younger maternal age, less maternal and paternal 
education, more paternal mental health problems, lower IQs, and higher teacher-rated ADHD and 
Oppositional Defiant Disorder (ODD) scores than those retained.  
Measurement 














Interview Schedule for Children – Parent version (DISC-P)13 and Young Adult version (DISC-
YA)13, instruments documented to have good reliability and validity, were completed by participants 
and parents. We used the oldest adult assessment point (12, 14, or 16 years) at which data were 
available. For the educational domain, we analyzed participant report of current educational 
attainment. Within the occupational domain, number of jobs, average job length, times fired or quit, 
current income, and public assistance status were chosen a priori. Military service counted as 
employment. Within the emotional functioning domain, the Impulsivity/Emotional Lability subscale 
of the CAARS (participant and parent report) and the Neuroticism subscale of the NEO-Five-Factor 
Inventory (participant report)14 were analyzed. We also examined past-year presence of any of eight 
DSM anxiety disorders or three DSM mood disorders from the DISC-YA. Within the substance use 
domain, participant report of DSM-IV substance use disorder in the past year from the DISC-YA 
included Alcohol Use Disorder (AUD), Marijuana Use Disorder (MUD), ‘other Substance Use 
Disorder’ (other SUD), including cocaine and hallucinogens, and ‘any Substance Use Disorder’ (any 
SUD), excluding nicotine. Within the legal domain, participant report of police contact (yes/no) and 
jail time (yes/no) during the past two years were analyzed. Within the sexual behavior domain, four 
outcomes were derived from the MTA Health Information and Demographic Survey: age of first 
sexual intercourse, number of sexual partners, number of pregnancies fathered or experienced by 
age 18, and number of offspring. Deaths were reported by site staff on a retention/attrition form. 
Determination of ADHD Symptom Persistence  
DSM-5 symptom-count criteria, i.e., 5 symptoms reported either by the participant or the 
parent in either the Inattention and/or Hyperactive-Impulsive domain on the CAARS, identified the 
symptom-persistent ADHD group. Symptom desistence was defined as neither ADHD domain 
threshold being exceeded by either source. In 23 cases in which self-report suggested no symptoms 














by participants.3,15  The rate of symptom persistence under this definition was 50% (n = 226), with 
symptom desistence characterizing the remaining 50% (n = 227). Impairment, though measured, 
was not used to define symptom persistence/desistence because functional outcomes, which reflect 
levels of impairment, are the focus of this paper. 
Analyses  
We used orthogonal comparisons to evaluate differences across multiple adult functional 
outcomes, comparing childhood diagnosis (ADHD vs. LNCG) and persistence subgroups of ADHD 
(Symptom Persistence vs. Symptom Desistence). Age at outcome assessment was covaried to adjust 
for “opportunity time” for educational attainment and number of jobs, sexual partners, pregnancies, 
etc. For binary outcomes, we used binary logistic regressions; for dimensional outcomes, linear 
regressions. Poisson regressions were used for non-normal distributions (e.g., number of offspring). 
The CAARS DSM-IV Hyperactive-Impulsive Symptom subscale was a covariate for analysis of the 
Impulsivity/Emotional Lability subscale to partial out impulsivity from emotional lability. We used 
the Benjamini-Hochberg False Discovery Rate (FDR) method to correct for multiple comparisons 
within each domain.16 All analyses were repeated, separately covarying for SES (income) and initial 
conduct disorder. 
RESULTS 
Educational Outcomes  
Overall, the LNCG had higher educational attainments than participants with ADHD (Table 
S1, available online). The majority of ADHD participants (61.7%) had a high school degree or less 
while the majority of LNCG participants completed at least some college (60.8%). Showing a 
stepwise pattern, 37.1% of the LNCG obtained a Bachelor’s degree compared to 17.8% (OR=2.7) of 















Occupational Outcomes  
In four of five analyses, the ADHD group differed significantly from the LNCG (number of 
jobs since previous assessment was not different) (Table 1). Effect sizes were small for average job 
length, number of times fired/quit since last assessment, and current income, but large for 
percentage receiving public assistance: 16.0% of ADHD participants vs. 3.2% of LNCG 
participants. For comparisons of the ADHD subgroups, a stepwise pattern emerged for the three 
significant outcomes: the subgroup with Symptom Persistence showed the worst outcomes and the 
LNCG participants the best (effect sizes were always largest between these two groups), with the 
Symptom-Desistent subgroup intermediate. Most group differences were statistically significant at 
p<.05 after correcting for multiple comparisons, but effect sizes were small (up to d =.41), except 
for receipt of public assistance in the past year (OR=8.7), for which Symptom Persistence =22.2%, 
LNCG=3.2%, and Symptom Desistence fell between at 9.6%.   
Emotional Outcomes  
The ADHD group scored significantly worse than the LNCG on Impulsivity/Emotional-
Lability (self- and parent-report) and Neuroticism, but not rates of mood or anxiety disorders (Table 
S2, available online).  The Symptom-Persistent subgroup scored worse on Impulsivity/Emotional 
Lability (self- and parent-report) and Neuroticism, and endorsed higher rates of mood (7.8 % vs. 
1.8%, OR=4.58) and anxiety disorders (14.2% vs. 5.0%, OR=3.12), than the Symptom-Desistent 
subgroup, which exhibited outcomes similar to the LNCG (see Figure 2).  
Legal Outcomes  
Participants with ADHD (13.6%) were more likely (p=.028) to report police contact than the 
LNCG (9.4%), but this difference was no longer significant after controlling for multiple 
comparisons (Table 2). Jail time did not differ significantly. Symptom-Persistent and Desistent 














Substance Use Outcomes  
The LNCG and ADHD groups did not differ significantly on any substance use measures 
(Table 2). The Symptom-Persistent subgroup displayed higher rates of MUD (26.7 % vs. 14.7%, p < 
.001), ‘other SUD’ (8.3% vs. 1.9%, p = .002) and ‘any SUD’ (38.5% vs. 28.7%, p = .004) than the 
Symptom-Desistent subgroup, which exhibited similar rates to the LNCG. The Symptom-Persistent 
subgroup was 2.6 times as likely as the LNCG to meet criteria for the MUD diagnosis, and 4.3 times 
as likely to have an ‘other SUD’.  
Sexual Behavior Outcomes  
All four ADHD-LNCG comparisons were significant: ADHD was associated with younger 
age at first intercourse, more sexual partners, increased risk of pregnancy, and greater number of 
offspring by age 18, covarying age (Table 3). Probands reported more multiple offspring (6.9% vs. 
1.7% for LNCG). The Symptom-Persistent subgroup was significantly different from the Symptom-
Desistent subgroup on age of first intercourse and marginally different on number of partners, but 
not risk of early pregnancy or number of offspring. Effect sizes were small/medium.  
Sensitivity Analyses  
Sensitivity analyses for all outcomes covaried SES (income) and initial conduct disorder 
separately (details are available in Supplement 1, available online). These did not alter the results 
except that job length was no longer significant after covarying conduct disorder, and risk of 
pregnancy and self-reported impulsivity-emotional lability on the CAARS were no longer 
significant when income was covaried.  
Deaths  
Although not statistically significant, the group comparison is striking, with 10 deaths in the 
ADHD group (3 suicides, 4 homicides, 2 driving-under-the-influence accidents, 1 hit-and-run) 















 The MTA, with 579 childhood-diagnosed, combined-type ADHD participants and 258 sex- 
and age-matched comparison participants without ADHD, provides the largest sample of 
prospectively-followed young adults to date; it is very ethnically and socioeconomically diverse, and 
thus by and large generalizable to an ADHD (combined-subtype) population. However, one needs to 
keep in mind that the subjects lost to follow-up (18% of the ADHD sample) were characterized by 
lower family income and parental education, more parental mental health problems, lower 
participant IQ, higher ADHD scores and higher rates of ODD than those retained. Because these are 
risk factors for poorer outcome, it is possible that a higher proportion of ADHD subjects would have 
had more negative outcomes had these subjects been retained.  
The large sample size allowed comparison not only of the ADHD vs. LNCG groups but also 
of subgroups of ADHD participants defined by persistence vs. desistence of symptoms into early 
adulthood. Symptom persistence was defined by DS -5 symptom criteria for adults, making it 
clinically relevant and permitting comparison with other outcome studies. 
Our findings extend those of previous studies by showing three patterns of outcomes. The 
most common pattern is characterized by the LNCG group having the best outcomes, the Symptom-
Persistent ADHD subgroup the worst, and the Symptom-Desistent subgroup falling between them. 
Obtaining a Bachelor’s degree, times fired/quit a job, current income, receiving public assistance, 
and risky sexual activity all followed this pattern, with moderate to large effect sizes between the 
LNCG and Symptom-Persistent ADHD groups, and smaller effect sizes between Symptom-
Desistent ADHD and the other two groups. This pattern shows that continuing ADHD symptoms 
have a significant negative impact on educational, occupational, and sexual functional domains by 
adulthood. Even if ADHD symptoms desist, however, the negative impact of earlier ADHD 














to treat continuing symptoms of ADHD and to focus on improving these functional outcomes early.  
In the second pattern, the LNCG and Symptom-Desistent ADHD group did not differ 
significantly but both functioned significantly better than the Symptom-Persistent ADHD group. 
This pattern was seen for emotional lability, neuroticism, anxiety and mood disorders, and substance 
use disorders. In this pattern, persistent ADHD symptoms continue to have a significant negative 
impact on emotional and substance use domains, but past ADHD symptoms do not appear to have a 
residual effect as found in the first pattern. Here, when ADHD symptoms desist, the functioning of 
young adults with previous ADHD approaches that of the comparison participants. This pattern 
illustrates the value of differentiating Symptom-Persistent vs. -Desistent ADHD subgroups in 
examining functioning and outcome. Persisting symptoms of ADHD may contribute to SUD risk 
either directly (e.g., impulsive decision-making) or indirectly (e.g., poor coping skills)17 or as a 
misguided attempt at self-medication. Moreover, Barkley and Fisher (2010)3 linked emotional 
impulsivity to persistence of ADHD symptoms in adulthood, and Swanson et al. (2014)7 linked poor 
response inhibition to increased self-harm in women with ADHD. Thus, continuing to treat ADHD 
symptoms to “remission” and not just “improvement” is clinically important because current 
symptom remission appears somewhat protective against anxiety, depression, and SUD. 
In the third pattern, no significant differences were noted among the three groups. Number of 
jobs held, alcohol use disorder, and jail time followed this pattern. Notably, the number of jobs held 
was not significantly different across groups although the times fired/quit, current income and 
receiving public assistance were significantly worse for the Symptom-Persistent subgroup. Possibly, 
with less education, greater emotional lability, and more SUD, this subgroup found it more difficult 
to find another job after being fired or impulsively quitting, such that the number of jobs held did 
not differ despite shorter job length. In fact, the increased use of public assistance suggests more 














will be explored in depth in a future paper.  
 Alcohol use disorder (AUD) was not higher for the ADHD vs. LNCG. Overall levels of 
AUD are high at this age18 which, coupled with social impairments that predict less drinking for 
some with ADHD,19 may explain our findings for alcohol. The illegal nature of marijuana use (at the 
time these data were collected) may partly be driving our findings due to the oft-cited contribution 
of conduct problems to ADHD-related risk of SUD. Issues related to self-control and impulsivity as 
well as self-medication for hyperactive-impulsive symptoms are also often implicated in marijuana 
use.20,21 More research is needed as the societal context of this drug changes. Similarly, 
incarcerations were rare and did not differ across the groups, possibly because the young adults may 
have been considered first time offenders and not generally given jail time early on.  
Our findings on the comparison of LNCG and ADHD groups are similar to other long-term 
prospective controlled follow-up studies.2–5,22 These studies all showed that adults who had 
childhood ADHD are more impaired, relative to comparison participants, in educational, 
occupational, and emotional domains. Some studies also showed similar findings for sexual 
behavior,3 whereas others did not.2 Mixed findings have also been reported for substance use.2,3,22   
Several studies6,7 have suggested a minority of children with ADHD have early adult 
outcomes comparable to children without ADHD. It may well be that these groups are characterized 
by ADHD symptom desistence. Generally, anxiety and mood disorder rates were not elevated in our 
ADHD group compared to the LNCG, but were higher in the Symptom-Persistent subgroup, and 
thus more tightly linked to current ADHD symptoms than to history of ADHD. Similar findings 
were reported in some previous adult ADHD outcome studies.2,4 However, other studies3,22 reported 
high rates of mood disorders in adults with ADHD compared to matched comparison participants. 
These discrepancies across studies may, once again, be a function of the proportion of Symptom 














current, or past 6 months) and locations of such investigations could also account for different 
findings. 
Few studies have explored the differences in multiple outcome areas in adulthood between 
ADHD subjects for whom symptoms persisted vs. desisted vs. a non-ADHD comparison group. Our 
large sample size allowed for these comparisons, providing insight into which functional areas are 
related to earlier ADHD symptoms, e.g., educational, occupational, and sexual behavior domains, 
and which are particularly influenced by current symptomatology, e.g., SUD and emotional 
domains.  
The large number of deaths in the ADHD group compared to the LNCG is striking (10 vs. 1) 
though it does not reach statistical significance. The higher death rates in participants with ADHD 
have also been documented in other follow-up studies,2,4 and alert us to the possible increased early 
mortality via accidents, suicides, or homicides in the ADHD population.  
The association of persistence of ADHD symptoms and negative adult outcomes is clear. 
However, we should point out that the persistence group also has more comorbidity, e.g., anxiety, 
depression, MUD, and these comorbidities may also be contributing to negative outcomes. A recent 
paper by Roy et al.23 explored childhood factors that may be associated with or contribute to 
persistence of ADHD symptoms in adulthood. Important predictive factors included baseline initial 
ADHD symptom severity, parental mental health, and parenting practices. Caye et al.24 identified 
severity of ADHD, treatment and comorbid conduct disorder and major depression as important 
predictors of persistence of ADHD into adulthood.  
A large, diverse, fairly representative sample and a matched local normative comparison 
group with a respectable retention rate are all strengths of the study. Whenever possible, 
standardized validated age-appropriate measures were used, with more than one informant. 














desistence ADHD subgroups. Finally, sensitivity analyses covaried all results separately on SES 
(income) and initial conduct disorder, which did not significantly alter most results, suggesting these 
factors were not responsible for the differences we documented.  
In the young adult follow-up period, the participants themselves were the principal 
informants of functional outcomes. Their reports may not have been completely accurate or 
objective because self-report biases are not uncommon in this population.25 However, more 
objective sources may also have flaws. Police records and other official records are often the “tip of 
the iceberg,” as many acts are either not detected or not officially reported.26 Furthermore, parents 
become less knowledgeable about certain aspects of the young adult’s life as their children age. 
Thus, conducting thorough assessments for adults with ADHD remains challenging. 
DSM-5 symptom criteria were used to define symptom persistence and desistence subgroups 
because of clinical relevance and future comparisons but alternative definitions (e.g., clinician gold 
standard) may offer additional insights. The contributions of psychiatric comorbidities both as 
predictors and as correlated outcomes are important areas that are being explored in other papers.  
Another limitation is that personality disorders, particularly antisocial personality disorders, 
were not evaluated as outcomes. It is thus unclear if this diagnosis differed in the persistent, 
desistent and LNCG groups, although other studies4 clearly suggest that antisocial personality 
disorder and symptom persistence often coexist.  
Effects of treatment on outcome were not specifically explored in this paper as this was 
addressed in detail by Swanson et al (submitted for review).27  In that paper, the authors showed that 
there were no treatment group differences after 3 year follow-up. Furthermore, after 14 months, all 
participants went to the community for treatment, where there may have been self-selection biases 
and documented less than optimal medication treatment.9 Lastly, there is a marked decline in 














often very intermittently. 
A final limitation is that the LNCG was recruited at 2 years rather than initially. It is unclear 
whether this would impact study results as the LNCG group were matched for age and sex, and 
attended the same schools.  
 This study extends previous longitudinal studies of ADHD by documenting three different 
patterns of adult outcomes. The most common, seen in educational, occupational, and 
sexual/reproductive domains, was characterized by LNCG participants functioning best, Symptom-
Persistent ADHD participants worst, and Symptom-Desistent ADHD participants between. Thus, 
some important outcomes are influenced additively by both current symptoms and residual effects of 
past symptoms.  
In the second pattern, seen with emotional lability, neuroticism, anxiety, mood, and 
substance use disorders, the LNCG and Symptom-Desistent ADHD group did not differ 
significantly, and both were significantly better than the Symptom-Persistent ADHD group.  This 
suggests that some negative outcomes are linked mainly to residual symptoms, so symptoms need to 
be treated to “remission” not just “improvement.”   
 The third pattern showed no significant differences among the three groups on number of 
jobs, AUD and jail time, probably due mainly to very high or very low frequency. 
 These findings suggest that functional outcomes in adults who were diagnosed with ADHD 
in childhood are not uniform but differ across domains, giving rise to different patterns of outcomes. 
The persistence or desistence of ADHD symptomatology in adulthood appears to influence these 
patterns of outcomes. Thus, both ADHD symptoms and functioning need to be targets of 
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Figure 1. Educational outcomes. ADHD = attention-deficit/hyperactivity disorder; LNCG = 
local normative comparison group.  
Figure 2. Emotional outcomes. Note: ADHD = attention-deficit/hyperactivity disorder; 















Table 1. Occupational Outcomes  
 
     ADHD Symptoms       
 LNCG (L) ADHD   Desistence (D) 
Persistenc
e (P)    Effect Sizes
b
 
 M (SD) M (SD) Ba (SE) p M (SD) M (SD) Ba (SE) p ∆R2 D-L P-L P-D 
Work History             
   Number of jobsc 2.1(1.3) 2.2(1.6) .08(.12) .495 2.3(1.6) 2.1(1.6) .20(.14) .151 .004 .11 .03 .13 
   Avg. job lengthc 422(325) 381(341) 60.14(27.4) .028 e 410(389) 351(291) 59.1(31.8) .063 .012 .03 .23 .17 
   Times fired/quitc .32(.64) .61(1.06) .29(.07) <.001e .47(.78) .70(1.17) .24(.08) .005e .033 .20 .40 .23 
   Past year income  4.0(2.20) 3.4(1.8) .81(.15) <.001e 3.6(1.7) 3.2(1.7) .44(.17) .011e .046 .19 .41 .26 
   Public assistanced 3.2% 16.0% 1.69(.42) <.001e 9.6 % 22.2% .98(.30) .001e .122 3.2 8.7 2.7 
 
Note. ∆R2 is the proportion of variance in the dependent variable explained by contrasts between local normative comparison group (LNCG), 
attention-deficit/hyperactivity disorder (ADHD) desistence and ADHD persistence after controlling for participant age. For categorical dependent 
variables, the Nagelkerke R2 is reported.  
a
 Betas presented in absolute value format. 
b Effect sizes for continuous dependent variables are Cohen’s d, calculated using a pooled standard deviation weighted by group size. Effect sizes 
for categorical dependent variables are odds ratios.  
c
 Since last assessment or high school, whichever is more recent.  
d Currently receiving public assistance or not, reported as a percentage who are. B coefficients are log-odds estimates from logistic regression.  

























Table 2. Legal and Substance Use Outcomes 
 
     ADHD Symptoms       
 
LNCG 




(P)    Effect Sizes
b
 
 % % Ba (SE) p % % Ba (SE) p ∆R2 D-L P-L P-D 
Legal             
Any police contact  9.4 13.6 .58(.26) .028c 13.3 13.7 .06(29) .844 .014 1.5 1.5 1.0 
Jail Time  2.3 3.6 .56(.50) .259 3.9 3.3 .15(.51) .765 .008 1.8 1.5 0.9 
Substance Use             
   AUD  20.4 20.3 .07(.21) .734 20.4 20.2 .03(.24) .886 <.001 0.9 1.0 1.1 
   MUD  12.3 20.1 .44(.24) .070 14.7 26.7 1.05(.26) <.001d .055 1.1 2.6 2.3 
Other SUD  2.1 4.8 .29(.59) .621 1.9 8.3 2.32(.76) .002d .100 0.8 4.3 5.5 
   Any SUD  26.0 33.1 .26(.19) .157 28.7 38.5 .61(.21) .004d .023 1.0 1.8 1.7 
 
Note. ∆R2 is the proportion of variance in the dependent variable explained by contrasts between local normative comparison group (LNCG), 
attention-deficit/hyperactivity disorder (ADHD) desistence and ADHD persistence after controlling for participant age. The Nagelkerke R2 is 
reported. “Other SUD" (where SUD is substance use disorder) includes such substances as cocaine and hallucinogens; "Any SUD" includes 
alcohol use disorder (AUD), marijuana use disorder (MUD), and Other SUD.  
a
 Betas presented in absolute value format. 
b Effect sizes are odds ratios.  
c Indicates that the contrast is statistically non-significant after applying the Benjamini-Hockberg false discovery rate (FDR) correction for multiple 
comparisons. 
d


















Table 3. Sexual Behavior Outcomes  
 
     ADHD Symptoms       
 LNCG (L) ADHD   Desistence (D) 
Persistence 
(P)    Effect Sizes
b
 
 M (SD) M (SD) Ba (SE) p  M (SD) M (SD) Ba (SE) p  ∆R2 D-L P-L P-D 
 Age first 
intercourse 17.2(2.3) 16.3(2.6) 1.31(.24) <.001
d
 16.6(2.6) 16.0(2.5) .55(.240) .037d .019 0.3 0.5 0.2 




0.3 0.4 0.2 




0.5 0.4 0.6 
# of Offspring .113(.37) .298(.67) -1.07(.26) <.001d .249(.57) .348(.77) .330(.18) .067 .005 0.5 0.4 0.7 
 
Note. ∆R2 is the proportion of variance in the dependent variable explained by contrasts between local normative comparison group (LNCG), 
attention-deficit/hyperactivity disorder (ADHD) desistence and ADHD persistence after controlling for participant age. For categorical dependent 
variables, the Nagelkerke R2 is reported.  
a
 Betas presented in absolute value format. 
b Effect sizes for continuous dependent variables are Cohen’s d, calculated using a pooled standard deviation weighted by group size. Effect sizes 
for categorical dependent variables are odds ratios.  
c Categorical dependent variable. Percentages are reported instead of means and standard deviations. B coefficients are log-odds estimates from 
logistic regression.  
d
























Table S1. Educational Outcomes 
 
     ADHD Symptoms       
 
LNCG 




e (P)    Effect Sizes
b
 
 % % Ba (SE) p % % Ba (SE) p ∆R2 D-L P-L P-D 
Education Level    1.29(.16) <.001c   .48(.19) .014c .10 2.7 7.4 2.8 
High School/Less 39.2 61.7   57.8 65.6       
   College/Trade 18.8 23.2   20.9 25.4       
   Bachelor’s Degree 37.1 12.9   17.8 8.0       
   Graduate Degree 5.0 2.2   3.6 0.9       
 
Note. ∆R2 is the proportion of variance in the dependent variable explained by contrasts between local normative comparison group 
(LNCG), attention-deficit/hyperactivity disorder (ADHD) desistence and ADHD persistence after controlling for participant age. The 
Nagelkerke R2 is reported.  
a
 Betas presented in absolute value format. 
b Effect sizes are odds ratios and represent probability of obtaining a Bachelor’s degree. D-L shows the odds ratio between the ADHD-
desistent subgroup and the LNCG; P-L shows the odds ratio between the ADHD-persistent subgroup and the LNCG; P-D shows the 
odds ratio between the ADHD-persistent and ADHD-desistent subgroups. 


























Table S2. Emotional Outcomes 
     ADHD Symptoms       
 
LNCG 




(P)    Effect Sizes
b
 
 M (SD) M (SD) Ba (SE) p M (SD) M (SD) Ba (SE) p ∆R2 D-L P-L P-D 
Emotional Functioning             
Impulsivity/Emotional 
Lability (CAARS-Parent)b 0.44(.48) 1.11(.79) .14(.04) <.001
d
 0.58(.42) 1.50(.77) .24(.06) <.001d .015 .31 1.64 1.42 
Impulsivity/Emotional 
Lability (CAARS-Self)b 0.42(.43) 0.73(.61) .07(.03) .027
d
 0.45(.40) 0.91(.65) .09(.04) .016d .005 .07 .88 .82 
Neuroticismb 1.31(.62) 1.49(.66) .17(.05) .001d 1.31(.60) 1.61(.67) .30(.06) <.001d .051 .00 .46 .47 
Anxiety Disorderc 8.1% 9.5% .14(.29) .630 5.0% 14.2 % 1.14(.37)  
.002d .057 .59 1.77 3.12 
Mood Disorderc 3.4% 4.8% .23(.43) .597 1.8% 7.8 % 1.52(.57) .007d .098 .54 1.98 4.58 
Note. Conners’ Adult ADHD (attention-deficit/hyperactivity disorder) Rating Scale (CAARS) DSM-IV Hyperactive-Impulsive 
subscale scores were also covaried when the Impulsivity/Emotional Lability subscale of the CAARS was considered to partial out 
variance accounted for by impulsivity. Item-level mean scores were considered for the Impulsivity/Emotional Lability (ranging from 
0-3) and Neuroticism (ranging from 0-4) subscales. LNCG = Local normative comparison group. Missing data carried forward from 
14 or 12 year assessments for CAARS analysis, and 14, 12, 10, and 8 for NEO analysis. ∆R2 is the proportion of variance in the 
dependent variable explained by contrasts between LNCG, ADHD desistence and ADHD persistence after controlling for participant 
age. For categorical dependent variables, the Nagelkerke R2 is reported.  
a
 Betas presented in absolute value format. 
b Effect sizes for continuous dependent variables are Cohen’s d, calculated using a pooled standard deviation weighted by group size. 
Effect sizes for categorical dependent variables are odds ratios. 
 
c Categorical dependent variable. Percentages are reported instead of means and standard deviations. B coefficients are log-odds 
estimates from logistic regression. 




















Results of Covarying Baseline Socioeconomic Status (Family Income) and Conduct Disorder  
 
For the attention-deficit/hyperactivity disorder (ADHD) and local normative comparison group (LNCG) comparison, all contrasts 
remained the same (significant or non-significant) even with false discovery rate (Benjamini and Hochberg, 1995) corrections, in the 




- High school or less 
- College/trade 
- Bachelor’s degree 
- Graduate degree 
 
Occupational Outcomes: 
- Number of jobs 
- Times fired/quit 
- Past year income 
- Public assistance 
 
Emotional Outcomes: 
- Impulsivity/emotional lability (parent-report) 
- Neuroticism 
- Anxiety disorder 
- Mood disorder  
 
Legal Outcomes: 
- Any police contact 
- Jail time 
 
Substance Use Outcomes:  
- Alcohol use disorder 














- Other substance use disorder 
- Any substance use disorder 
 
Sexual Behavior Outcomes: 
- Age at first intercourse 
- Number of partners 
- Number of offspring 
 
* Covarying baseline income made:  
1. Self-reported impulsivity/emotional lability no longer significant 
2. Risk of pregnancy by age 18 no longer significant 
 
* Covarying baseline conduct disorder made:  
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